Skip to main content

Doing now what patients need next

Pioneering diagnostics and pharma to create a healthier future for everyone

A family gathers around an outdoor table, enjoying a meal. A man hugs a smiling boy, while two women sit nearby, all appearing content and joyful.

In the spotlight

Roche publishes its half year results for 2026

Roche reports +6% (CER) sales growth in the first six months of 2026. Commenting on the results, CEO Thomas Schinecker said: “Our strong momentum continued in the first half of the year, driven by a 6% sales increase at constant exchange rates and significant positive pipeline development.

How we improved outcomes for patients around the world

With our combined strengths in Diagnostic and Pharmaceuticals, we worked to provide real and positive change for patients, the people they love and the professionals who care for them. Discover the highlights in our Annual Report.

Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.

Portrait of Thomas Schinecker

Dr Thomas Schinecker

CEO Roche Group

Investor information

We are Roche

We combine life-changing diagnostics and medicines to take on the toughest healthcare challenges, those that place the greatest strain on patients, families, communities, and health systems. 

Guided by the experiences of patients, we are determined to prevent, stop and cure diseases so people can live healthier, longer lives.

Man holding a surfing board smiling with a ocean in the background.

Read our stories

Shape the future of healthcare

Join our global team of innovators, scientists, and changemakers